Inactief instrument

Andere talen Alzheon, Inc.

Aandelen

ALZH

US00168L1017

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Alzheon, Inc. Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer's Disease	30/04
Alzheon, Inc. announced a financing transaction	27/02
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer	05/12
Alzheon, Inc. to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer's Disease Conference	17-10-23
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer?s Disease Day, and BIO Investor Forum	26-09-23
Alzheon Reports Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 in Patients with Early Alzheimer's Disease	13-09-23
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet	11-07-23
Alzheon, Inc. to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study At American Academy of Neurology Conference in Boston	18-04-23
Alzheon, IncAnnounces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease	06-12-22
Alzheon, Inc. announced that it expects to receive $50.004201 million in funding	30-11-22
Alzheon, Inc. Reports Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral Alz-801 (Valiltramiprosate) in Patients with Early Alzheimer’S Disease	20-09-22
Alzheon, Inc Appoints Glenn Pauly as Head of Commercial	20-09-22
Alzheon, Inc. to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ -801 (Valiltramiprosate) Oral Tablet At 2022 Alzheimer’S Association International Conference	26-07-22
Alzheon, Inc. announced that it has received $50.000004 million in funding	14-04-22
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update and Industry-Leading Disease Modifying Effects from Phase 2 Trial in Patients with Early Alzheimer’s Disease At AD/PD and NDDS Scientific Conferences	08-03-22
Alzheon Reports Disease Modifying Effects from Phase 2 Biomarker Trial of Oral Tablet ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease	08-02-22
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer?s Disease Conference	01-11-21
Alzheon Appoints Adem Albayrak as Head of Operations	13-09-21
Alzheon, Inc. Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease	23-06-21
Alzheon, Inc. Announces Publication of Peer-Reviewed Scientific Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis	23-06-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Alzheon, Inc.

Aandelen

ALZH

US00168L1017

Andere talen

Filters